Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director · PRESIDENT AND CEO | February 02, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date February 02, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 850,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 850,000 · Balance 850,000 F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Performance Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.65 · Expires 2036-02-01 | Direct | 275,000 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 275,000 · Balance 275,000 F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. F3: Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F2: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.
F3: Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantPerformance Stock Options (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001831218-26-000002 · form4-02042026_090201.xml · derivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2036-02-01 F2 · derivative.exercise_date: The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. F3 · derivative.exercise_date: Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $25.65 | $0.00 |
DisclosureSEC source: 0001831218-26-000002 · form4-02042026_090201.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GiftCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001831218-25-000004 · form4-12302025_091209.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,650 F1 · kind: Reflects the gift of common stock to a charitable donor advised fund. F2 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001415889-25-006147 · form4-03032025_090310.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,267 | $9.39 | $11,897.13 |
DisclosureSEC source: 0001415889-24-029024 · form4-12122024_121245.xml · nonDerivative · entry 4 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,662 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 55,907 | $8.66 | $484,154.62 |
DisclosureSEC source: 0001415889-24-029024 · form4-12122024_121245.xml · nonDerivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,929 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 52,328 | $9.37 | $490,313.36 |
DisclosureSEC source: 0001415889-24-029024 · form4-12122024_121245.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,836 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.87 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 00:52 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 204,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029024 · form4-12122024_121245.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,164 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 315,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria. F2 · balance_after: Includes 1,489 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 621,500 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001415889-24-002607 · form4-02052024_050202.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,500 Underlying: Common Stock · 621,500 shares Expires 2034-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 22, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 27,932 | $13.90 | $388,254.80 |
DisclosureSEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 4 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,925 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.16. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,602 | $15.29 | $39,784.58 |
DisclosureSEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,857 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $15.29, and the range of prices was between $15.20 and $15.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 26,691 | $14.84 | $396,094.44 |
DisclosureSEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,459 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $14.84, and the range of prices was between $14.20 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 110,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,150 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 315,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. F2 · balance_after: Includes 5,000 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2022 and 12,621 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:29 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006284 · doc4.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 22:51 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009880 · form4-09222022_030957.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,279 F1 · price: The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 21:35 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009915 · form4a-09232022_020934.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,279 F1 · kind: This amendment is being filed solely to correct the transaction code in column 3 of Table I from code "A" to code "P". F2 · price: The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F3 · balance_after: Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:02 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 812,250 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001055 · form4-02032022_040258.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,250 Underlying: Common Stock · 812,250 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 22:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001415889-21-004885 · form4-10152021_031031.xml · derivative · entry 4 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,316 Underlying: Common Stock · 5,000 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 22:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 351 | $31.17 | $10,940.67 |
DisclosureSEC source: 0001415889-21-004885 · form4-10152021_031031.xml · nonDerivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $31.17, and the range of prices were between $31.00 and $31.28. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 22:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 4,649 | $30.42 | $141,422.58 |
DisclosureSEC source: 0001415889-21-004885 · form4-10152021_031031.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,865 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $30.42, and the range of prices were between $30.00 and $30.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 22:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,000 | $4.82 | $24,120.00 |
DisclosureSEC source: 0001415889-21-004885 · form4-10152021_031031.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 23:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001415889-21-004613 · form4-09292021_040935.xml · derivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,316 Underlying: Common Stock · 1,085 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 23:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,085 | $30.07 | $32,625.95 |
DisclosureSEC source: 0001415889-21-004613 · form4-09292021_040935.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 23:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 1,085 | $4.82 | $5,234.04 |
DisclosureSEC source: 0001415889-21-004613 · form4-09292021_040935.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,631 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · derivative · entry 6 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,401 Underlying: Common Stock · 2,631 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,631 | $30.00 | $78,930.00 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · nonDerivative · entry 4 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 2,631 | $4.82 | $12,691.94 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · nonDerivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 413 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · derivative · entry 5 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,032 Underlying: Common Stock · 413 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 413 | $30.08 | $12,423.04 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,274 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $30.08, and the range of prices were between $30.00 and $30.12. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 413 | $4.82 | $1,992.31 |
DisclosureSEC source: 0001415889-21-004306 · form4-09092021_010907.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:16 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 871 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001415889-21-004247 · form4-09032021_020903.xml · derivative · entry 3 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,445 Underlying: Common Stock · 871 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:16 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 871 | $30.05 | $26,173.55 |
DisclosureSEC source: 0001415889-21-004247 · form4-09032021_020903.xml · nonDerivative · entry 2 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,274 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $30.05, and the range of prices were between $30.01 and $30.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:16 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 871 | $4.82 | $4,201.70 |
DisclosureSEC source: 0001415889-21-004247 · form4-09032021_020903.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,625 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $45.63 | $0.00 |
DisclosureSEC source: 0001209191-21-021109 · doc4.xml · derivative · entry 1 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on March 15, 2022 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 23:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 538,020 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059509 · doc4.xml · derivative · entry 5 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,020 Underlying: Common Stock · 538,020 shares Expires 2030-11-17 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 23, 2020 Filed Nov 19, 2020 23:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,649 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-20-059509 · doc4.xml · derivative · entry 4 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,316 Underlying: Common Stock · 51,649 shares Expires 2030-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 23, 2020 Filed Nov 19, 2020 23:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 51,649 | $4.82 | $249,154.78 |
DisclosureSEC source: 0001209191-20-059509 · doc4.xml · nonDerivative · entry 1 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2020 Filed Nov 19, 2020 23:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 1,027,965 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-20-059509 · doc4.xml · derivative · entry 3 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,965 Underlying: Common Stock · 1,027,965 shares Expires 2030-09-18 F2 · derivative.exercise_date: (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. Read SEC document |
| September 19, 2020 Filed Nov 19, 2020 23:41 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 82,931 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-20-059509 · doc4.xml · derivative · entry 2 Bohen Sean · CIK 0001831218 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,931 Underlying: Common Stock · 82,931 shares Expires 2030-09-18 F1 · derivative.exercise_date: 20,732 of the shares subject to the option vest on September 1, 2021 and 20,733 of the shares subject to the option vest on January 1 of each of 2022, 2023 and 2024, subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.